Joseph Sirven, M.D., neurologist and epilepsy specialist at Mayo Clinic in Arizona, discusses the newly FDA approved device for the treatment of drug-resistant epilepsy. He includes information on patients who would be candidates for RNS as well as the benefits of this treatment option.
Share this Video
Related Videos In Epilepsy
Highlights from EAN 2023!
Jacqueline French, AAN 2023: XEN1101, a novel potassium channel modulator for the treatment of focal epilepsy
In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]
Jacqueline French, AAN 2023: X-TOLE phase 2b open-label extension trial of XEN1101 in focal epilepsy – interim data
The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy. In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!